Product Information

BANZEL 200 MG TABLET is a brand product labeled by Eisai Inc., priced at $12.6103 per EA under NDC 62856058252. Its NADAC has been published 631 times since Nov 28, 2013.

FDA first approved this application on Nov 14, 2008. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

The High Outlier badge above means this manufacturer's average price in the rufinamide market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.

BANZEL 200 MG TABLET

rufinamide
$12.6103per EA
High Outlier

Strength

200 mg/1

Manufacturer

Eisai Inc.

NDC

62856058252

Classification

Brand

Dosage Form

TABLET, FILM COATED

Route

ORAL

Effective Date

8/19/2026

Active Ingredients

RUFINAMIDE

Approval Type

New Drug (NDA)

FDA Application

NDA021911

FDA Approved

11/14/2008

TE Code

AB

On Market Since

11/14/2008

Price Statistics

The NADAC for BANZEL 200 MG TABLET has been published 631 times since Nov 28, 2013, and over the history we have for it it has risen 154.9%. The table below summarizes its recorded NADAC range and movement.

Current price$12.6103 per EA
All-time high$12.6907 (Nov 16, 2022)
All-time low$4.9463 (Nov 28, 2013)
52-week high$12.6164
52-week low$12.5976
Median price$11.4990
Average price$10.5915
Largest weekly change+9.9% (Feb 4, 2015)
Weeks tracked631
Tracking sinceNov 28, 2013

Price History

1W

+0.0%

1M

+0.0%

3M

+0.1%

6M

+0.0%

1Y

-0.0%

3Y

+0.0%

5Y

-0.1%

All

+154.9%

Generic Alternatives

The matcher finds 3 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 93% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Related Drugs

Same classification

No related drugs found.

Frequently asked questions

What is the NADAC price of BANZEL 200 MG TABLET?

The current National Average Drug Acquisition Cost (NADAC) for BANZEL 200 MG TABLET, manufactured by Eisai Inc., is $12.6103 per EA (NDC 62856058252), effective Aug 19, 2026.

How has the price of BANZEL 200 MG TABLET changed over time?

Over the history we have for it, the NADAC for BANZEL 200 MG TABLET has risen 154.9%. It has been tracked across 631 weekly CMS publications since Nov 28, 2013.

What are the highest and lowest recorded NADAC prices for BANZEL 200 MG TABLET?

Since Nov 28, 2013, the NADAC for BANZEL 200 MG TABLET has ranged from a low of $4.9463 (Nov 28, 2013) to a high of $12.6907 (Nov 16, 2022), with a median of $11.4990 per EA.

Are there cheaper alternatives to BANZEL 200 MG TABLET?

Yes. 3 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, RUFINAMIDE 200 MG TABLET, is $0.8320 per EA — about 93% below BANZEL 200 MG TABLET.

Who manufactures BANZEL 200 MG TABLET?

BANZEL 200 MG TABLET (NDC 62856058252) is labeled by Eisai Inc., and CMS classifies it as a brand product.